title: Evaluation of the renal function using cystatin C level in the patients receiving cisplatin-based chemotherapy.
abstract: OBJECTIVE
  There are some data regarding the role of cystatin C, a cysteine proteinase inhibitor, in determining the glomerular filtration rate (GFR) more accurately. We aimed to evaluate the correlation of serum cystatin C levels with the serum creatinine levels and GFR calculated by Cockcroft-Gault and modification of diet in renal disease (MDRD) formulations in the patients who received cisplatin-based chemotherapy. We also intended to demonstrate its potential use in the early prediction of the renal function changes in these patients.
  
  
  METHODS
  In the study, 34 patients receiving cisplatin-based chemotherapy with various malignancies were included. The levels of cisplatin were determined prior to the chemotherapy and at the end of cisplatin infusion during the therapy. GFR was calculated by Cockcroft-Gault and MDRD formulations prior to the therapy and at the end of the third course.
  
  
  RESULTS
  A statistically significant linear correlation was found between the serum levels of cystatin C and creatinine prior to the chemotherapy (r = 0.42, p = 0.013). However, there was no correlation among the level of cystatin C subsequent to the cisplatin infusion and serum creatinine level following the third course and MDRD and creatinine clearance-Cockcroft-Gault formulations.
  
  
  CONCLUSIONS
  Even though the serum cystatin C levels were correlated with the serum creatinine levels in our study, it was concluded that it was not an appropriate parameter to predict the potential impairments in the renal function during the chemotherapy.
authors.affiliation: Department of Medical Oncology, Kahramanmaraş Sütçü Imam University Faculty of Medicine, Kahramanmaraş, Turkey. tugbasan@yahoo.com
authors.forename: F T
authors.initials: FT
authors.lastname: Kos
authors.forename: M A N
authors.initials: MA
authors.lastname: Sendur
authors.forename: S
authors.initials: S
authors.lastname: Aksoy
authors.forename: S
authors.initials: S
authors.lastname: Sezer
authors.forename: B
authors.initials: B
authors.lastname: Civelek
authors.forename: O
authors.initials: O
authors.lastname: Yazici
authors.forename: S
authors.initials: S
authors.lastname: Yaman
authors.forename: T
authors.initials: T
authors.lastname: Eren
authors.forename: N
authors.initials: N
authors.lastname: Zengin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D002945:Cisplatin / Q000009:adverse effects*; D055316:Cystatin C / Q000097:blood*; D005260:Female; D006801:Humans; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D051437:Renal Insufficiency / Q000139:chemically induced* / Q000175:diagnosis*; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D055316:Cystatin C; D002945:Cisplatin